Currently in the United States, no existing regulatory guidelines set a standardized risk assessment to determine the safety and efficacy of herbs.
The U.S. Food and Drug Administration (FDA) recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The FDA is committed to sound, science-based policy.
Other than one prescription drug product
to treat rare, severe forms of epilepsy, the FDA has not approved any other CBD products, and there is very limited available information about CBD, including about its effects on the body. There are no other clinical indications for CBD.
JDC pediatrics follows the policies of the FDA and does not recommend use of CBD in children unless they are prescribed CBD by a licensed physician for one of the severe forms of epilepsy.